Skip to main content
. 2023 Mar 9;13(5):1099–1111. doi: 10.1007/s13555-023-00913-3

Fig. 1.

Fig. 1

Flow chart of patient disposition. aOne patient was randomized to RZB 360 mg but did not receive treatment. bOne patient completed week 16 but did not enter the open-label period. “Other” includes COVID-19 infection, logistical restrictions due to COVID-19, and study termination. RZB Risankizumab